logo
Sensational dire wolf claims questioned by scientists: 'Extinction is forever'

Sensational dire wolf claims questioned by scientists: 'Extinction is forever'

Yahoo08-04-2025

Sensational claims by a United States company that it has brought an extinct animal back from the dead have been questioned by scientists. Rather than recreating a dire wolf, as claimed by Colossal Biosciences, several leading New Zealand-based animal experts claim the company has simply produced a modern-day gray wolf 'with dire wolf-like characteristics'.
'This is not a de-extincted dire wolf, rather it's a 'hybrid'. And importantly, it's what they think are the important dire wolf-like characteristics,' University of Otago paleogeneticist Associate Professor Nic Rawlence said.
Because dire wolves were wiped out 12,500 years ago, the snippets of its DNA that remain have been heavily degraded and can't be faithfully sequenced. Dire wolves diverged from gray wolves up to six million years ago, and Rawlence has dismissed the notion that 20 changes to 14 genes to the latter species is significant enough to claim the former has been brought back from extinction.
Colossal regularly makes international headlines for its ongoing work to bring the Tasmanian tiger, dodo, and wooly mammoth back from extinction.
On Tuesday, it's CEO Ben Lamm announced its unexpected dire wolf news. "Our team took DNA from a 13,000-year-old tooth and a 72,000-year-old skull and made healthy dire wolf puppies," he said.
While it's achievements like this that make headlines, the company is also quietly funding important scientific advancements in wildlife protection. In March, it announced a $US3 million investment in the University of Melbourne, which is working to genetically modify frogs so they aren't killed by chytrid fungus, a disease that has already led to the decline of 500 amphibian species, including 90 extinctions.
Also on Tuesday, Colossal revealed it had cloned red wolves, the world's most critically endangered wolf. Importantly, this achievement adds new genetic complexity to a species that was almost declared extinct in the 1960s and is threatened by a lack of diversity in the DNA of the tiny population that remains.
While many scientists are in awe of the company's advancements in genetic engineering, it's the claims that it makes about de-extinction that are frequently called into question.
In March, when the company revealed it had created a wooly mouse with similar traits to a mammoth, it was commended for continuing to remind the community about the "power" of genetic modifications. But a leading molecular genetics expert at the University of NSW, predicted the de-extinction of mammoths was decades away.
'It's not a matter of changing seven genes, you would have to change thousands, and you have to do the reproductive biology too. Overall, it would be like stacking up ladders to get to the moon,' Professor Merlin Crossley said.
🦈 Theory emerges after massive shark found bitten in half
😳 Aussie woman's 'incredible' 500-year-old discovery
🐕 Rare find in Aussie bush by sniffer dog
Colossal's dire wolf claims have sparked similar scepticism from other New Zealand-based experts. Professor Philip Seddon from the University of Otago's department of zoology said the company's creation no doubt involved 'amazing technological breakthroughs', but he dismissed the notion that its new pups, Romulus, Remus, and Khaleesi are real dire wolves.
'Certainly, this involves advances in genetic technology, and these might have applications for the conservation of existing species — but the return of dire wolves? No,' he said.
'In the same way that Colossal's plans for woolly mammoths and dodos will involve the genetic modification of related species. We have GMO wolves, and might one day have GMO Asian elephants, but for now extinction really is forever."
Associate Professor Michael Knapp from the University of Otago's Department of Anatomy agreed.
'These new dire wolves are genetically almost certainly closer to gray wolves than to ancient dire wolves, but they look more like dire wolves than gray wolves. These are not the dire wolves that went extinct more than 10,000 years ago, as the press release may suggest,' he said.
Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Yahoo

timean hour ago

  • Yahoo

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Eastern WA researchers fight cyber threats at aging U.S. hydropower system
Eastern WA researchers fight cyber threats at aging U.S. hydropower system

Yahoo

time6 hours ago

  • Yahoo

Eastern WA researchers fight cyber threats at aging U.S. hydropower system

Washington generates more hydroelectricity than any other state, so it is fitting that research to protect the critical infrastructure responsible for generating this power is happening right here in the Tri-Cities, at the Department of Energy's Pacific Northwest National Laboratory. Researchers at PNNL are combining their knowledge of the hydropower system and expertise in cybersecurity to secure the operational technology of the nation's hydropower fleet. Their work to protect these facilities helps ensure the continued generation of affordable electricity that powers our homes and factories. It also safeguards a key source of dispatchable power — generation that can be ramped up and down as needed to balance supply and demand — that enhances grid reliability and resilience. The federally managed hydropower projects have an average age of about 65 years, so researchers tasked with protecting them must bridge the past to the future. Efforts to adapt aging systems to thwart today's constantly evolving cyber threats include developing a suite of cybersecurity tools, an operational training model and a monitoring system. To make it easier for operators who may need to respond to and recover from a cyber incident, researchers assembled and integrated guidance from several agencies and created a cyber-physical framework and roadmap for the nation's entire fleet. They also prepared and shared a step-by-step desk guide for navigating a cyberattack. Fundamental to this work was an assessment of the connections and interactions among the cyber and physical components at hydropower facilities of all kinds. By studying a representative sample of plants with a wide range of ages and uses, researchers found that they could be binned into just nine distinct cyber-physical configurations. This allows operators to more easily identify shared risks and potential mitigations. In a separate effort to train cybersecurity professionals working on critical infrastructure, PNNL researchers developed a series of test platforms. These platforms, known as skids, are scaled-down, functional models that enable realistic exercises without putting real infrastructure at risk. Examples of PNNL-developed skids include models of a water treatment facility, the Class 1 freight rail network and a hydropower plant. Each can be 'attacked' by cyber means to explore vulnerabilities and mitigation strategies. The hydropower skid and associated training scenarios were designed with input from regional hydropower plant operators, including Spokane-based Avista Corporation and Grant County Public Utility District. Complete with wicket gates, turbines and other components needed to generate power, as well as small, representative industrial control systems, the skid allows operators to see the effects of unauthorized cyber access and learn how to manage the risk. Trainees can watch water levels above and below the miniature dam as the control systems undergo a simulated cyberattack. They can monitor relays in the substation that might trip, watch for flooding or erosion and see how the power grid responds. They also get a firsthand look at how their simulated responses impact the system. PNNL's support in protecting hydropower plants also extends to an award-winning technology called SerialTap. This palm-sized device serves as a data collector, allowing modern network cybersecurity tools to monitor dispersed serial communication devices and legacy industrial control systems. SerialTap makes it possible to detect cyberattacks and network anomalies so that analysts and operators can respond more quickly and effectively. The technology will be tested by a commercial partner whose affiliate companies own and operate 85 hydroelectric facilities in the United States. As the complexity and connectedness of the critical infrastructure we depend on for a strong economy increase, so does the risk of cyber threats with higher consequences. Experts at PNNL are developing novel approaches to protect, detect and recover from potential cyberattacks at the hydroelectric facilities that produce nearly 6 percent of the nation's total electricity — and more than 60 percent of the power generated in the great state of Washington. Steven Ashby is director of the Pacific Northwest National Laboratory in Richland.

Japanese Lunar Lander Crashes In Second Failed Mission
Japanese Lunar Lander Crashes In Second Failed Mission

Yahoo

time6 hours ago

  • Yahoo

Japanese Lunar Lander Crashes In Second Failed Mission

A private Japanese lunar lander crashed during an attempted touchdown on the moon Friday. This marks the second failed mission for the Tokyo-based global lunar exploration company, ispace. The lander, named Resilience, lost communication less than two minutes before its scheduled landing in Mare Frigoris, a flat, crater-filled region on the moon's northern near side. A preliminary analysis indicated the laser system for measuring altitude malfunctioned, causing the lander to descend too fast. 'Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface,' ispace said in a statement. 'This is the second time that we were not able to land. So we really have to take it very seriously,' CEO and founder Takeshi Hakamada told reporters, per Associated Press. He apologized to contributors and added that the mission was 'merely a stepping stone' to a larger lander planned for 2027 with NASA involvement. 'Engineers did everything they possibly could' to ensure success, he said minutes before the attempted landing. The 7.5-foot Resilience, launched in January from Florida on a SpaceX rocket, carried an 11-pound, four-wheeled rover named Tenacious, built by ispace's Luxembourg subsidiary. The rover, equipped with a high-definition camera and a shovel for NASA to collect lunar soil, was designed to operate for two weeks during the moon's daylight period. It also carried a toy-size Swedish-style red cottage, dubbed Moonhouse by artist Mikael Genberg, for placement on the lunar surface. The mission's $16 million payload included scientific instruments from Japanese firms and a Taiwanese university. The failure follows ispace's first lunar crash in 2023, caused by inaccurate altitude readings. 'Truly diverse scenarios were possible, including issues with the propulsion system, software or hardware, especially with sensors,' Chief Technology Officer Ryo Ujiie said at a press conference. Jeremy Fix, chief engineer for ispace's U.S. subsidiary, noted last month that the company, with a mission cost less than the first's $100 million, lacks 'infinite funds' and cannot afford repeated failures. 'We're not facing any immediate financial deterioration or distress because of the event,' CFO Jumpei Nozaki said, citing investor support. However, space shares faced heavy sell orders and were poised for a 29% drop. As of Thursday, their market capitalization was over 110 billion yen ($766 million). The crash marks another setback in the commercial lunar race, which began in 2019. U.S. firms Firefly Aerospace and Intuitive Machines achieved successful landings in March, though Intuitive's lander toppled in a crater. Japan's space agency, JAXA, landed its SLIM probe last year, joining Russia, the U.S., China, and India as the only nations with successful robotic lunar landings. 'Expectations for ispace have not faded,' Japanese Prime Minister Shigeru Ishiba posted on X, reported Reuters. Ispace remains committed to NASA's Artemis program, with plans for a third mission in 2027. 'NASA increasingly needs private companies to improve cost efficiency for key missions with limited budgets,' Hakamada said, referencing proposed U.S. budget cuts. Two U.S. companies, Blue Origin and Astrobotic Technology, aim for moon landings by year's end following Astrobotic's 2024 failure.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store